Manulife is launching a preventative opioid management program, extending its Vitality program to group benefits plans and partnering with digital health company Akira Health. The opioid management program features a two-step system. The first ensures plan members who start opioid treatment do so with a short-term supply, while the second encourages using short-acting opioids at the outset. […]
Specialty medications and high-cost drugs for common conditions are driving up private plan drug spending, according to Express Scripts Canada’s annual drug trends report. The report found the rapid increases in drug spending for private plans over the last 20 years have started to slow. The average annual drug spending per plan member was up just 0.9 per cent […]
Canadian insurers expect health costs to rise by 11.55 per cent this year, according to a new report by Accompass Inc. The annual survey determines the anticipated year-over-year cost increase or decrease — or health trend factor — by asking insurers to examine their businesses and take various factors into account, including legislation and reforms, economic events […]
Health Canada has proposed amendments to the Food and Drug Regulations that would make it easier for drug companies to get authorization to produce generic versions of brand name drugs. The amendments would allow Health Canada to more quickly to approve generic drug applications that have the same active ingredients as their brand name equivalent […]
While some say a single-payer system would mean reduced drug prices and expenditures, others argue it could have unintended consequences, particularly for private plan sponsors. Marc-André Gagnon, associate professor at Carleton University’s school of public policy and administration: Canada’s drug coverage is a patchwork without coherence or purpose. Some think more patches can solve the […]
In September 2018, Health Canada approved, for the first time, the use of a chimeric antigen receptor T cell (CAR-T) therapy. Called Kymriah, it treats pediatric and young adult leukemia and adult lymphoma. The federal regulator is also reviewing a second gene therapy, called Yescarta, for an aggressive kind of non-Hodgkin lymphoma. Both therapies are […]
On Feb. 27 in Toronto, the 2019 Employers Cancer Care Summit addressed cancer-related concerns tied to benefits plans in the workplace. Here’s what you missed: Gap services one solution to evolving developments in immunotherapy When it comes to cancer treatment, immunotherapy is a game changer with an exciting future ahead, according to Dr. Jeff Rothenstein. […]
Though many plan sponsors are still using step therapy to manage drug plan costs, pharmacogenetic testing is receiving attention as more providers enter the market, lower the cost and familiarize employers and insurers with the technology. As it becomes more sophisticated, there’s more information about how pharmacogentic testing works, says Sandra Ventin, associate vice-president at […]
The Competition Bureau has discontinued an inquiry into allegations that Janssen Inc. inhibited the Canadian market for biosimilar products that compete with its biologic product Remicade. Given the significant impact of biologics in Canada, the report highlights some of the competition issues related to the biologics and biosimilars market. Although the bureau expressed concerns about the […]
As a job title, ‘drug case manager’ can imply different things across the health-care and benefits industries. In Canada, a drug case manager may be part of a drug manufacturer’s patient support program or an insurance company’s preferred pharmacy network, while hospitals have case managers at various levels, says Suzanne Nagy, drug consulting leader for […]